Items where authors include "Chandran, S."

Article

Boddy, S.L., Simpson, R.M. orcid.org/0000-0003-1677-5938, Walters, S.J. et al. (38 more authors) (2025) Further development of a patient-reported outcome measure to assess the impact of oral secretion problems in people living with MND. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. ISSN 2167-8421

Khan, Z.M., Ball, C., Saeed, D. et al. (8 more authors) (2025) Appraisal of current surgical guidelines for inflammatory bowel disease using the AGREE-S instrument: A scoping review. Colorectal Disease, 27 (1). e17258. ISSN 1462-8910

Saez-Atienzar, S., Souza, C.D.S., Chia, R. et al. (323 more authors) (2024) Mechanism-free repurposing of drugs for C9orf72-related ALS/FTD using large-scale genomic data. Cell Genomics, 4 (11). 100679. ISSN 2666-979X

Blackstone, J., Williams, T., Nicholas, J.M. et al. (59 more authors) (2024) Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK. BMJ Open, 14 (9). e086414. ISSN 2044-6055

Taş, G. orcid.org/0009-0008-2409-0246, Westerdijk, T., Postma, E. et al. (87 more authors) (2024) Computing linkage disequilibrium aware genome embeddings using autoencoders. Bioinformatics, 40 (6). btae326. ISSN 1367-4803

Young, C.A. orcid.org/0000-0003-1745-7720, Rog, D.J., Sharrack, B. et al. (33 more authors) (2023) Correlates and trajectories of relapses in relapsing–remitting multiple sclerosis. Neurological Sciences, 45 (5). pp. 2181-2189. ISSN 1590-1874

Barton, S.K., Magnani, D., James, O.G. et al. (17 more authors) (2021) Transactive response DNA-binding protein-43 proteinopathy in oligodendrocytes revealed using an induced pluripotent stem cell model. Brain Communications, 3 (4). fcab255. ISSN 2632-1297

Perkins, E.M., Burr, K., Banerjee, P. et al. (11 more authors) (2021) Altered network properties in C9ORF72 repeat expansion cortical neurons are due to synaptic dysfunction. Molecular Neurodegeneration, 16 (1). 13.

Mosenzon, O., Blicher, T.M., Rosenlund, S. et al. (113 more authors) (2019) Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. The Lancet Diabetes & Endocrinology, 7 (7). pp. 515-527. ISSN 2213-8587

Marshall, I., Thrippleton, M.J., Bastin, M.E. et al. (17 more authors) (2018) Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging study. Journal of Neurology, 265 (8). pp. 1795-1802. ISSN 0340-5354

Al-Chalabi, A. orcid.org/0000-0002-4924-7712, Andersen, P.M., Chandran, S. et al. (38 more authors) (2017) July 2017 ENCALS statement on edaravone. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 18 (7-8). pp. 471-474. ISSN 2167-8421

McLaughlin, R.L., Schijven, D., van Rheenen, W. et al. (433 more authors) (2017) Genetic correlation between amyotrophic lateral sclerosis and schizophrenia. Nature Communications, 8. 14774.

McGeachan, A.J., Hobson, E.V., Al-Chalabi, A. et al. (19 more authors) (2016) A multicentre evaluation of oropharyngeal secretion management practices in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. ISSN 2167-8421

McDermott, C.J., Shaw, P.J., Stavroulakis, T. et al. (24 more authors) (2015) Gastrostomy in patients with amyotrophic lateral sclerosis (ProGas): a prospective cohort study. Lancet Neurology, 14 (7). pp. 702-709. ISSN 1474-4422